Company Insights

GKOS customer relationships

Explore interactive graphBrowse insights index
GKOS customer relationship map

Glaukos (GKOS) customer relationships: reimbursement progress and commercial cadence

Glaukos sells ophthalmic implants and related therapies primarily through a U.S.-focused direct commercial organization, monetizing via device and procedural revenues to ambulatory surgery centers, hospitals and physician practices, while expanding international reach through subsidiaries and distributors. Revenue is driven by product adoption in surgical settings, reimbursement wins with Medicare Administrative Contractors (MACs), and the commercial rollout of new therapies such as iDose TR. For investors seeking a customer-relationship lens on execution, the reimbursement cadence and MAC engagements are the operational heartbeat that converts clinical innovation into predictable procedure volume. Learn more about how we surface these relationships at https://nullexposure.com/.

How Glaukos sells and what that implies for contracts and concentration

Glaukos operates a single operating segment focused on ophthalmic therapies, selling predominantly in the United States through a direct sales force and in select international markets via subsidiaries and independent distributors. According to Glaukos’ public disclosures, U.S. sales represented about 70% of net sales in 2024 and no single customer accounted for more than 10% of net sales, which signals a broad-based commercial channel rather than dependence on a small set of purchasers. The company is simultaneously launching iDose TR after a controlled commercial start in February 2024, which positions the business in a ramping commercial stage for that product line.

These operating facts create distinct business-model characteristics for customers and contracts:

  • Contracting posture: transactional and channel-driven. Revenue flows from procedure-based purchases by ASCs, hospitals, and physician-run practices rather than long-term supply contracts with anchor customers.
  • Concentration: dispersed buyer base. The absence of a >10% single-customer concentration reduces counterparty risk, while institutional customers (ASCs/hospitals) remain critical to unit economics.
  • Criticality: high to customers at the point of care. Devices and implants are procedure-enabling products; reimbursement acceptance and MAC coding decisions materially affect adoption and unit volumes.
  • Maturity: established commercial model with targeted product ramp. The company’s direct-sales U.S. footprint is mature for legacy products, while iDose TR is in an early-to-mid ramping phase that will determine near-term growth trajectory.

MAC wins and the short list of contractors that matter

Reimbursement recognition by Medicare Administrative Contractors (MACs) and regional payors is the proximate determinant of utilization. Management emphasized MAC activity on the Q4 2025 earnings call transcript, tying growth to professional fees established with several MACs and progress toward favorable determinations with others. The transcript is the central source for the customer relationships tracked below (Q4 2025 earnings call transcript).

NGS

NGS was added to the company’s reimbursement mix in late 2025, and management credited that addition with contributing to momentum from Q3 into Q4 and into early 2026. According to the Q4 2025 earnings call transcript, NGS’s inclusion provided immediate near-term benefits to procedure trends. (Q4 2025 earnings call transcript via InsiderMonkey: https://www.insidermonkey.com/blog/glaukos-corporation-nysegkos-q4-2025-earnings-call-transcript-1698091/)

Novitas

Novitas is one of the MACs where Glaukos has established professional fees, and management cited ongoing growth driven by these MAC-level reimbursements. The Q4 2025 call highlights Novitas alongside other MACs as drivers of incremental reimbursement-led revenue. (Q4 2025 earnings call transcript)

Noridian

Noridian is likewise listed as a MAC where Glaukos has secured professional fees, contributing to the company’s Medicare reimbursement footprint and supporting procedure adoption in Noridian-serviced jurisdictions. (Q4 2025 earnings call transcript)

First Coast

First Coast is part of the same cohort of MACs where professional fees are in place, and management noted continued growth in the MAC markets where these fees have been established. (Q4 2025 earnings call transcript)

WPS

Management reported concrete progress with WPS and assessed that they are making meaningful advances alongside Palmetto and CGS; WPS is explicitly singled out as an active engagement where Glaukos is progressing toward a coverage or fee determination. (Q4 2025 earnings call transcript)

Palmetto

Palmetto is described as a near-term objective: management stated the company is “on the doorstep” with Palmetto and expects a decision in days to weeks, indicating an imminent potential reimbursement conversion that would be material to adoption in Palmetto-serviced regions. (Q4 2025 earnings call transcript)

CGS

CGS is another MAC where management reported active progress and near-term momentum, naming CGS alongside WPS and Palmetto as front-of-the-line reimbursement targets. (Q4 2025 earnings call transcript)

Mid-read resource: for a consolidated presentation of these customer and reimbursement relationships, visit https://nullexposure.com/.

What the relationships mean for investors

These MAC-level relationships translate directly into the demand curve for Glaukos products because coverage and professional fee recognition remove a principal barrier to adoption in outpatient surgical settings. The operational consequences are twofold:

  • Near-term upside if Palmetto and CGS convert to favorable coverage, as management has flagged that these would lift utilization in their respective geographies and reduce friction for surgeons and ASCs to adopt iDose TR or other procedural products.
  • Execution risk tied to the iDose TR ramp and reimbursement cadence. iDose TR is in an early commercial phase, and its growth depends on successful MAC coverage rollouts and continued sales-force penetration into ASCs and practices.

Other company-level signals from filings reinforce this view: Glaukos’ sales are U.S.-centric, its go-to-market is direct in the United States with distributor supplementation internationally, and no single external customer concentration dominates revenue, which cushions downside if a single MAC outcome is delayed.

Investment takeaways and next steps

  • Reimbursement progression is the principal operational catalyst: MAC wins like Novitas, Noridian, First Coast, NGS, WPS, Palmetto and CGS are functionally sales enablers rather than end customers.
  • Diversified buyer base reduces single-customer concentration risk, but the company remains exposed to the timing of regional MAC decisions and the commercial ramp of iDose TR.
  • Monitor Palmetto and CGS outcomes as high-impact near-term events, and track procedure volumes in MAC-serviced geographies for signs of durable adoption.

For further analysis of customer relationships and how payor dynamics affect revenue trajectories, return to our hub at https://nullexposure.com/.

Final call to action: if you are evaluating reimbursement-driven medtech investments or operational risk in commercial rollouts, use the Glaukos relationship map on our site to align coverage events with valuation milestones — visit https://nullexposure.com/ for the full view.